InvestorsHub Logo
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: genisi post# 448

Friday, 02/19/2010 6:15:14 AM

Friday, February 19, 2010 6:15:14 AM

Post# of 3994
Tidbits from GENZ Q4 CC:

Cerezyme - 85% of the patients in the US are back on therapy, GENZ also believes that the 85% number is representative on a global basis. GENZ will ship Cerezyme at approximately 50% of current global demand for 4 infusion periods (8 weeks), in order to build a small amount of inventory.

Fabrazyme - has a slower recovery cycle. About 300 patients switched to Replagal. GENZ will extend the 30% Fabrazyme allocation until May (good for Shire).

http://seekingalpha.com/article/189139-genzyme-corporation-q4-2009-earnings-call-transcript?source=yahoo&page=-1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News